Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

Tango Therapeutics priced an underwritten offering of 18.2 million shares at $30.00 per share and pre-funded warrants, expected to raise approximately $600 million in gross proceeds. The offering is expected to close on June 11, 2026, with J.P. Morgan, Leerink Partners, Cantor, and Stifel serving as joint bookrunning managers.